Sign up
Pharma Capital

Abzena CFO 'thrilled' with investor response to £25mln raise

Julian Smith, CFO of Abzena plc (LON:ABZA), discusses plans by the life sciences group to raise £25mln that will help accelerate the business towards “sustainable profitability”.

 

 

View full ABZA profile

Abzena plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.